LBRX

LB PHARMACEUTICALS INC LBRX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-51.60M

Quarter to Jun 30

Free cash flow

$-37.99M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$965.33M total
Deep Track Capital, LP
$108.82M0.0%
BlackRock, Inc.
$88.74M+10.7%
RA CAPITAL MANAGEMENT, L.P.
$71.68M0.0%
Trails Edge Capital Partners, LP
$49.43M+15.4%
JPMORGAN CHASE & CO
$48.87M+4.9%
Commodore Capital LP
$48.68M0.0%
TCG Crossover Management, LLC
$46.97M-21.3%
Caligan Partners LP
$46.67M0.0%
Spruce Street Capital LP
$44.66M0.0%
Nantahala Capital Management, LLC
$34.17M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$31.52M+8.6%
BALYASNY ASSET MANAGEMENT L.P.
$29.91M-0.2%
Alyeska Investment Group, L.P.
$28.04M0.0%
Vivo Capital, LLC
$25.96M0.0%
Nan Fung Group Holdings Ltd
$20.47M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$19.89M+18.2%
STATE STREET CORP
$19.54M+19.4%
Logos Global Management LP
$18.99M-36.1%
GOLDMAN SACHS GROUP INC
$18.71M+58.5%
JENNISON ASSOCIATES LLC
$17.55M+0.5%
GREAT POINT PARTNERS LLC
$10.30M+5.7%
BOOTHBAY FUND MANAGEMENT, LLC
$8.95MNew
MILLENNIUM MANAGEMENT LLC
$8.41M+89.3%
AMERIPRISE FINANCIAL INC
$7.38M+110.0%
CITADEL ADVISORS LLC
$7.01M-48.2%
See all 115 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/LBRX

Earnings Per Share

13fpro.ai/company/LBRX

Loading ratio trend…

LBRX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About LB PHARMACEUTICALS INC (LBRX): stock profile, AI score and financials

LB PHARMACEUTICALS INC (LBRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. LBRX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), LB PHARMACEUTICALS INC reports net income of $-51.6M, free cash flow of $-38.0M. Top institutional holders of LBRX by reported 13-F value include Deep Track Capital, BlackRock, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. LBRX trades on the Nasdaq exchange and files with the SEC under CIK 1691082. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LB PHARMACEUTICALS INC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1691082 →